Promoter Hypermethylation and Underexpression of Patched Homolog 1 in Pancreatic and Colorectal Cancers: A Cross-Sectional Study

Promoter Hypermethylation and Underexpression of Patched Homolog 1 in Pancreatic and Colorectal Cancers: A Cross-Sectional Study

OBJECTIVE Patched homolog 1 (PTCH1) - a trans-membrane protein is a tumor suppressor which negatively regulates Hedgehog signaling pathway. The present study aimed to investigate the promoter hypermethylation and protein expression pattern of PTCH1 in Pancreatic cancer (PC) and Colorectal cancer (CRC). METHODS Promoter hypermethylation of PTCH1 gene was analyzed using Methylation-Specific Polymerase Chain Reaction and protein expression pattern was studied using western blotting. RESULTS Promoter hypermethylation of the PTCH1 gene was found in 42.42% (14/33) and 55.73% (34/61) of Pancreatic and Colorectal tumor samples, respectively. A significant correlation was found between PTCH1 hypermethylation and smoking status in PC while PTCH1 hypermethylation in CRC was significantly correlated with late-stage disease and lymph node metastasis. PTCH1 protein was under expressed in 30.3% (10/33) and 50.8 % (31/61) of Pancreatic and Colorectal tumor samples, respectively. Methylation analysis of PTCH1 in Pancreatic adenocarcinoma cell line 1 (PANC-1) and Colorectal adenocarcinoma cell line (HT-29) revealed hemi methylation in PANC-1, complete methylation in HT-29 and methylation was clearly associated with loss of expression. CONCLUSION Our results indicate that epigenetic silencing of the PTCH1 promoter and concomitant loss of PTCH1 protein expression may play an important role in the development and progression of these cancers.

___

  • 1. Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 2006;5:1026– 33.
  • 2. Varjosalo M, Taipale J. Hedgehog signaling. J Cell Sci 2007;120:3–6.
  • 3. Ingham PW, Nakano Y, Seger C. Mechanisms and functions of Hedgehog signalling across the metazoa. Nat Rev Genet 2011;12:393–406.
  • 4. Lee RT, Zhao Z, Ingham PW. Hedgehog signalling. Dev Camb Engl 2016;143:367–72.
  • 5. Barakat MT, Humke EW, Scott MP. Learning from Jekyll to control Hyde: Hedgehog signaling in development and cancer. Trends Mol Med 2010;16:337–48.
  • 6. Sadikovic B, Al-Romaih K, Squire J, Zielenska M. Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics 2008;9:394–408.
  • 7. Pak E, Segal RA. Hedgehog signal transduction: Key players, oncogenic drivers, and cancer therapy. Dev Cell 2016;38:333–44.
  • 8. Hsia EY, Gui Y, Zheng X. Regulation of Hedgehog signaling by ubiquitination. Front Biol 2015;10:203–20.
  • 9. Pellegrini C, Maturo MG, Di Nardo L, Ciciarelli V, Gutiérrez García-Rodrigo C, Fargnoli MC.Understanding the molecular genetics of basal cell carcinoma. Int J Mol Sci 2017;18:2485.
  • 10.Zuo Y, Song Y. Detection and analysis of the methylation status of PTCH1 gene involved in the hedgehog signaling pathway in a human gastric cancer cell line. Exp Ther Med 2013;6:1365–8.
  • 11.Pandith AA, Siddiqi MA. Burden of cancers in the valley of Kashmir: 5 year epidemiological study reveals a different scenario. Tumour Biol 2012;33:1629–37.
  • 12.Sproul D, Meehan RR. Genomic insights into cancerassociated aberrant CpG island hypermethylation. Brief Funct Genomics 2013;12:174–90.
  • 13.Varjosalo M, Taipale J. Hedgehog: Functions and mechanisms. Genes Dev 2008;22:2454–72.
  • 14.Peng L, Hu J, Li S, Wang Z, Xia B, Jiang B, et al. Aberrant methylation of the PTCH1 gene promoter region in aberrant crypt foci. Int J Cancer 2013;132:E18–25.
  • 15.Cretnik M, Musani V, Oreskovic S, Leovic D, Levanat S. The patched gene is epigenetically regulated in ovarian dermoids and fibromas, but not in basocellular carcinomas. Int J Mol Med 2007;19:875–83.
  • 16.Chakraborty C, Dutta S, Mukherjee N, Samadder S, Roychowdhury A, Roy A, et al. Inactivation of PTCH1 is associated with the development of cervical carcinoma: Clinical and prognostic implication. Tumour Biol 2015;36:1143–54.
  • 17.Lee KW, Pausova Z. Cigarette smoking and DNA methylation. Front Genet 2013;4:1–11.
  • 18.Ishiyama A, Hibi K, Koike M, Fujiwara M, Kodera Y, Ito K, et al. PTCH gene expression as a potential marker for esophageal squamous cell carcinoma. Anticancer Res 2006;26:195–8.
  • 19.You S, Zhou J, Chen S, Zhou P, Lv J, Han X, et al. PTCH1, a receptor of Hedgehog signaling pathway, is correlated with metastatic potential of colorectal cancer. Ups J Med Sci 2010;115:169–75.
  • 20.Hammons G, Lyn-Cook B. Epigenetics in tobacco smoke toxicology. Curr Top Toxicol 2011;7:63–77.
  • 21.Breitling LP, Yang R, Korn B, Burwinkel B, Brenner H. Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. Am J Hum Genet 2011;88:450–7.
  • 22.Smith CJ, Hansch C. The relative toxicity of compounds in mainstream cigarette smoke condensate. Food Chem Toxicol 2000;38:637–46.
  • 23.Suter MA, Aagaard K. What changes in DNA methylation take place in individuals exposed to maternal smoking in utero? Epigenomics 2012;4:115–8.
  • 24.Wolf I, Bose S, Desmond JC, Lin BT, Williamson EA, Karlan BY, et al. Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer. Breast Cancer Res Treat 2007;105:139–55.
Türk Onkoloji Dergisi-Cover
  • ISSN: 1300-7467
  • Başlangıç: 2015
  • Yayıncı: Ali Cangül
Sayıdaki Diğer Makaleler

Promoter Hypermethylation and Underexpression of Patched Homolog 1 in Pancreatic and Colorectal Cancers: A Cross-Sectional Study

Rauf Ahmad WANI, Madiha NIYAZ, Mosin Saleem KHAN, Syed MUDASSAR, Aaliya SHAH, Omar Javid SHAH, Syed BESINA

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma

Yağmur MİNARECİ, Samet TOPUZ, Sezai VATANSEVER, Nail PAKSOY, Erdem BEKTAŞ, Naziye AK, Ferhat FERHATOĞLU, Esra AYDIN, İzzet DOĞAN, Mert KARACA, Hilal OĞUZ SOYDİNÇ, Hamdullah SÖZEN, Pınar MUALLA SAİP

The Effect of Henna in Nail Changes Due to Paclitaxel Treatment

Gülbeyaz CAN, Emel Emine KAYIKÇI

Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Gökhan ÖZYİĞİT, Ivane KILADZE, Pavol DUBINSKY, Nenad FILIPOVIĆ, Branislav JEREMIĆ

Prediction of Survival and Progression-free Survival Using Machine Learning in Stage III Lung Cancer: A Pilot Study

Güntülü AK, Melek YAKAR, Durmuş ETİZ, Muzaffer METİNTAŞ, Şenay YILMAZ, Özer ÇELİK

Prediction of Response to Neoadjuvant Chemoradiotherapy with Machine Learning in Rectal Cancer: A Pilot Study

Özer ÇELİK, Bartu BADAK, Alaattin ÖZEN, Evrim YILMAZ, Melek YAKAR, Durmuş ETİZ, Deniz KÜTRİ

Increased Levels of Anxiety, Depression, and Secondary Trauma in Radiation Oncologists during COVID-19 Pandemic: A Preliminary Report from Turkey

Yasemin BÖLÜKBAŞI, Yakup ALBAYRAK, Uğur SELEK, Nülifer KILIÇ DURANKUŞ, Nihan POTAS, Duygu SEZEN, Eyüb Yaşar AKDEMİR, Erkan TOPKAN, Şükran ŞENYÜREK

The Relationship of Ki-67 Over-expression with Clinicopathological Prognostic Parameters in Invasive Breast Carcinomas

Şennur İLVAN, Tülin ÖZTÜRK, Hale DEMİR, Buğra Taygun GÜLLE

Therapeutic Benefit of Intracavitary-interstitial Brachytherapy in Cervical Cancer Patients with Small and Large High-risk Clinical Target Volume

Makbule TAMBAŞ

Compatibility of MRI and Pathological Tumor Regression Grading in Patients with Locally Advanced Rectal Cancer After Undergoing Neoadjuvant Chemoradiotherapy

Ebru AKAY, İpek Pınar ARAL, Alaettin ARSLAN, Saliha KARAGÖZ EREN, Gamze TÜRK, Nail ÖZHAN